

Pharma in brief - Canada

Updated guidelines for Ontario formulary drug submission released

Summary

The Ontario Ministry of Health and Long-Term Care recently updated the Ontario Guidelines for Drug Submission and Evaluation (“**Guidelines**”). These Guidelines govern drug submissions for inclusion on the Ontario Drug Benefit Formulary or for listing as an interchangeable drug.

Despite various amendments to the regulations under the *Ontario Drug Benefit Act* and the *Drug Interchangeability and Dispensing Fee Act* (“**Regulations**”), this is the first time the Guidelines have been updated since 2000.

Background

The Guidelines provide practical information and guidance to manufacturers making drug submissions to the province of Ontario in order to have drug products listed on the Ontario Drug Benefit Formulary or as interchangeable products under the *Drug Interchangeability and Dispensing Fee Act*.

The changes

This update to the Guidelines consolidates changes made to the Regulations as well as related changes to submission policy. The Guidelines do not address recent proposed changes to the Regulations intended to streamline generic interchangeability (found [here](#)).

The Guidelines can be found at the link below and include an executive summary of these changes.

Highlights of changes to the Regulations since 2000 include:

- exemption from the requirement to provide *in-vivo* bioequivalence studies for dermatological glucocorticoids and certain aqueous solutions;
- limiting the price for most interchangeable drug products to 25% of the price of the original product;
- a rapid review process for single-source products that can take place prior to receiving a Notice of Compliance from Health Canada if certain criteria are met;
- a requirement that manufacturers confirm that no rebates were provided to listed persons and that the product is not a private label product; and
- allowing the Executive Officer to consider making an interchangeability designation for products containing the same amounts of the same or similar active ingredients in the same or similar dosage form.

Highlights of changes to submission policy since 2000 include:

- streamlined processes in listing single-source products that have been reviewed by the Common Drug Review or the pan-Canadian Oncology Drug Review, and multiple-source products that have received a Declaration of Equivalence from Health Canada;
- limitations that have been imposed on the consideration of non-prescription medications and natural health products;
- a requirement that manufacturers advise that there are no outstanding patent issues; and
- a challenge mechanism for non-streamlined multi-source product submissions.

Link:

The Guidelines can be found here: [Ontario Guidelines for Drug Submission and Evaluation](#)

For more information, please contact your IP/Life sciences or healthcare practice professional at Norton Rose Fulbright Canada LLP.

For a complete list of our IP team, [click here](#). For a complete list of our Life sciences and healthcare team, [click here](#).

Norton Rose Fulbright Canada LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright South Africa Inc and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients.

References to "Norton Rose Fulbright", "the law firm", and "legal practice" are to one or more of the Norton Rose Fulbright members or to one of their respective affiliates (together "Norton Rose Fulbright entity/entities"). No individual who is a member, partner, shareholder, director, employee or consultant of, in or to any Norton Rose Fulbright entity (whether or not such individual is described as a "partner") accepts or assumes responsibility, or has any liability, to any person in respect of this communication. Any reference to a partner or director is to a member, employee or consultant with equivalent standing and qualifications of the relevant Norton Rose Fulbright entity.

The purpose of this communication is to provide general information of a legal nature. It does not contain a full analysis of the law nor does it constitute an opinion of any Norton Rose Fulbright entity on the points of law discussed. You must take specific legal advice on any particular matter which concerns you. If you require any advice or further information, please speak to your usual contact at Norton Rose Fulbright.